Nasdaq
$5.91▼ 0.08%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $581.3MShares out 98.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 4d agoAfter-hours26.10.21 05:054Ownership#●●●
Solid Biosciences Inc.
Insider Gabriel Brooks of Solid Biosciences Inc. reported a change in beneficial ownership of securities as of October 18, 2026. This filing is a standard Form 4 report disclosing changes in executive shareholdings.…more
$5.91-0.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6After-hours26.10.07 05:354Ownership
Solid Biosciences Inc.
Director Ian F. Smith of Solid Biosciences Inc. reported a change in beneficial ownership of securities as of October 2, 2026. This filing is a Form 4 disclosure regarding insider share transactions.…more
$5.91-0.08%vs prev closeView filingShare - 8.6After-hours26.08.07 06:158-KKey event
Solid Biosciences Inc.
Solid Biosciences는 2026년 8월 6일, 제프리스(Jefferies LLC)와의 기존 판매 계약에 따라 최대 2억 달러 규모의 보통주를 추가로 발행 및 매각하기 위한 투자설명서 보충 서류를 제출했습니다. 회사는 기존에 8,500만 달러 규모의 주식을 매각 완료했으며, 이번 조치를 통해 추가적인 자본 조달을 진행할 예정입니다.…more
$5.91-0.08%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.20 21:00#●●●#●●●
Solid Biosciences to Present Gene Therapy Research at ESGCT 2026
Solid Biosciences will present seven research abstracts at the ESGCT Annual Congress, focusing on its SGT-003 program and next-generation delivery and manufacturing platforms. These presentations represent ongoing scientific progress rather than immediate clinical or financial milestones.…more
$5.91-0.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.1After-hours26.10.02 05:05
●●●●●●●● ●●●●● ●●●●●●
Solid Biosciences has granted 8,150 restricted stock units (RSUs) to a newly hired employee as an employment inducement. This grant follows standard Nasdaq listing rules for equity-based compensation to attract talent.…more
$5.91-0.08%vs prev close - 8.6After-hours26.08.07 05:08
●●●●●●●● ●●●●● ●●●●●●
솔리드 바이오사이언스는 뒤센 근이영양증 치료제 SGT-003의 임상 순항과 함께 2028년 중반까지 운영 가능한 자금을 확보했다고 밝혔습니다. 연말 FDA와 가속 승인 경로를 논의할 예정이며, 주요 파이프라인의 임상 데이터 발표를 앞두고 있습니다.…more
$5.91-0.08%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report